65 results about "Kidney dysfunction" patented technology

The present inventions relate to therapeutic compositions comprising, and methods utilizing, arachidonic acid derivatives and analogs for treatment of patients demonstrating symptoms of pathological conditions. Specifically, the inventions relate to therapeutic compositions for activating transient receptor potential vanilloid-1 channels (TRPV1). Additionally, therapeutic compositions are provided for increasing TRPV1-type responses. These pathological conditions include, but are limited to, hypertension, in particular salt induced hypertension, and cardiovascular complications, including myocardial infarction, kidney dysfunction, diabetes, and inflammation. Further, the inventions relate to drug screening methods for providing additional therapeutic compounds.

The present invention relates, in general, to perioperative bleeding and, in particular, to methods of identifying individuals at risk of perioperative bleeding. The present invention relates, in general, to perioperative renal dysfunction and, in particular, to methods of identifying individuals at risk of perioperative renal dysfunction. The present invention relates, in general, to perioperative stroke and, in particular, to methods of identifying individuals at risk of perioperative stroke.

The invention provides a preparation method of a traditional Chinese medicine for treating blood stasis type reflux oesophagitis, and belongs to the technical field of preparation methods of traditional Chinese medicines. Currently, omeprazole is adopted to treat blood stasis type reflux oesophagitis, and contraindicated for use by patients allergic to the medicament, patients with serious renal insufficiency, pregnant women and infants. The preparation method is characterized by comprising the following steps of immersing the following 35 Chinese medicines in water, namely trogopterus dung, pseudo-ginseng, circium japonicum, camellia, common cephalanoplos herb, osbeckia chinensis, folium artemisiae argyi, cactus, hairyvein agrimony, rhizoma bletillae, stove, carbonized hair, rumex japonicus, marmor serpentinatum, radix boehmeriae, madder, salvia plebeian, hollyhock flower, eclipta, clove, fiveleaf akebia fruit, illicium verum, murraya jasminorage, aspongopus, sword bean, elecampane, szechwan Chinaberry fruit, mysorethorn, three-nerved spicebush root, rhizoma nardostachyos, ambergris, radix curcumae, peach kernels, safflower and liquorice; decocting with slow fire; filtering and removing slag to obtain decoction, which is the traditional Chinese medicine for treating blood stasis type reflux oesophagitis. The Chinese medicine lotion has the advantages of small toxic and side effect of prepared Chinese medicine decoction, short course of treatment and high cure rate.

The pharmaceutical composition comprising the compound of the invention having 8-azaprostaglandin skeleton represented by formula (I) (wherein, all the symbols have the same meanings as that of the specification.) a salt thereof, a solvate thereof or a cyclodextrin clathrate thereof, or a prodrug thereof and them as active ingredient have EP4 agonistic action and thus are considered useful for the prevention and / or treatment of immunological diseases, asthma, neuronal cell death, arthritis, lung failure, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, liver damage, acute hepatitis, nephritis, renal insufficiency, hypertension, myocardial ischemia, systemic inflammatory response syndrome, sepsis, hemophagous syndrome, macrophage activation syndrome, Still's disease, Kawasaki disease, burn, systemic granulomatosis, ulcerative colitis, Crohn's disease, hypercytokinemia at dialysis, multiple organ failure, shock and glaucoma, etc. Furthermore, the compounds also have an action of accelerating bone formation, so it is expected to be useful for the prevention and / or treatment of diseases associated with loss in bone mass, for example, primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss, osteonecrosis, bone formation after bone operation, alternative treatment for bone grafting.

A method for distinguishing between kidney dysfunctions in a mammal, including pre-renal azotemia, an acute renal injury that may progress to acute renal failure, and chronic kidney disease, using a urinary or circulating NGAL assay result that is compared to a predetermined NGAL cutoff level, and a single serum or plasma creatinine measurement. Typically the single creatinine measurement cannot distinguish acute renal injury from chronic kidney disease or pre-renal azotemia, a single measurement of urinary NGAL, combined with the single serum or plasma creatinine measurement, has sufficient sensitivity and specificity to distinguish acute renal injury from normal function, prerenal azotemia, and chronic kidney disease and predicts poor inpatient outcomes. Patients admitted to the emergency department of the hospital with any of acute kidney injury, prerenal azotemia, chronic kidney disease, or even normal kidney function, can be evaluated based on the single measurements of urinary or circulating NGAL, and serum or plasma creatinine. Urinary NGAL level is highly predictive of clinical outcomes, including nephrology consultation, dialysis, and admission to the intensive care unit.

The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.

The present invention provides an improved comprehensive method of assessing an individual's risk of developing CVD through analysis of multiple factors know to be associated with the development of cardiovascular disease. The factors include the classic Framingham factors of an individual's age, blood pressure, total cholesterol (TC), high-density lipoprotein (HDL) cholesterol, history of diabetes and history of cigarette smoking, in addition to factors know to be associated with increased risk of CVD including inflammation, insulin resistance, obesity, kidney dysfunction.

A method for distinguishing between kidney dysfunctions in a mammal, including pre-renal azotemia, an acute renal injury that may progress to acute renal failure, and chronic kidney disease, using a urinary or circulating NGAL assay result that is compared to a predetermined NGAL cutoff level, and a single serum or plasma creatinine measurement. Typically the single creatinine measurement cannot distinguish acute renal injury from chronic kidney disease or pre-renal azotemia, a single measurement of urinary NGAL, combined with the single serum or plasma creatinine measurement, has sufficient sensitivity and specificity to distinguish acute renal injury from normal function, prerenal azotemia, and chronic kidney disease and predicts poor inpatient outcomes. Patients admitted to the emergency department of the hospital with any of acute kidney injury, prerenal azotemia, chronic kidney disease, or even normal kidney function, can be evaluated based on the single measurements of urinary or circulating NGAL, and serum or plasma creatinine. Urinary NGAL level is highly predictive of clinical outcomes, including nephrology consultation, dialysis, and admission to the intensive care unit.

The invention discloses a cefotiam-hydrochloride-containing medicine preparation which is composed of an active component cefotiam hydrochloride, basic amino acid, and anhydrous sodium carbonate. The weight ratio of cefotiam hydrochloride (calculated according to cefotiam) to basic amino acid to anhydrous sodium carbonate is 1:0.4-0.6:0.05-0.15. A preparation method provided by the invention is substantially advantaged in that: (1) vacuum pumping is not needed after product sub-packaging, such that processes are reduced; (2) when the medicine is dissolved, the generation of a large amount of carbon dioxide is prevented, such that the danger for cefotiam medicine liquid to be sprayed from a bottle is avoided; (3) when the cefotiam preparation is diluted into various fluid replacements (including glucose solutions, electrolyte solutions or amino acid preparations), the amount of generated carbon dioxide is extremely low, such that clarity observation of intravenous infusion is not affected; (4) the dosage of anhydrous sodium carbonate is low, such that the possibility of alkalosis is avoided; and (5) the dosage of sodium ions is reduced, such that the preparation is suitable for patients with cardiac or renal insufficiency, edema patients, neonates, pregnant women, and the aged. Therefore, the application scope of the preparation is expended.

The invention relates to a Chinese medicinal preparation for treating kidney diseases and process for preparation, wherein the medicament is prepared from the following Chinese medicinal herbs (by weight portion): red sage root 20-30 parts, barbat skullcap 5-10 parts, safflower 5-10 parts, Japanese felt fern leaf. 5-10 parts, honeysuckle flower 5-10 parts, rheum officinale 10-15 parts, capsule of weeping forsythia 5-10 parts, licorice root 3-6 parts, poria cocos wolf 10-15 parts, panax notoginseng saponins 1-1.5 parts.

The invention discloses a type of polyethylene glycol erythropoietin, which is prepared from non-glycosylated rhEPO(rhngEPO) or point mutant thereof, and N-terminal amino of single and single chain PEG molecule having molecular weight greater than 20kDa or mercapto of cysteine mutational state by fixed point coupling, wherein the olyethylene glycol erythropoietin has the molecular structural formula of CH3-(CH2CH2-O)n-(CH2)r-NH-rhngEPO or CH3-(CH2CH2-O)n-X-S-rhngEPOm, wherein n is 100 to 2,200, r is 0 to 4, and X is S or C. The PEG-rhngEPO or PEG-rhEPOm molecule simultaneously has long-acting preparation characteristics such as long acting, high efficiency and low immunogenicity, and establishes foundation for preparing parent long-acting preparation for treating anemia caused by chronic renal insufficiency, tumor, anemia caused by AIDS chemotherapy, marrow brain nerve damage, and selective operation auto-transfusion.

The invention discloses a preparation method of a traditional Chinese medicine for treating constipation-predominant reflux esophagitis and belongs to the technical field of preparation methods of traditional Chinese medicines. At present, bismuth potassium citrate is usually employed for treating the constipation-predominant reflux esophagitis, and the contraindication is that allergies, patients with severe renal impairment and pregnant patients are disabled. The technical scheme of the preparation method comprises: taking senna leaf, cape jasmine fruit, pagodatree pod, garden burnet root, Chinese arborvitae twig, immature bitter orange, officinal magnolia bark, longstamen onion bulb, areca peel, peach seed, Chinese angelica, figwort root, black sesame, hemp fruit, Chinese dwarf cherry seed, honey, apricot seed, coffee senna seed, common alstonia bark or leaf, common lophatherum herb, mung bean, mongolian dandelion herb, stonecrop, shortstalk slimtop meadowrue root, breynia fruticosa, small-leaved desmodium, physalis alkekengi, corydalis saxicola bunting, uniflower swisscentaury root, olive, lemmaphyllum microphyllum presl, creeping rostellularia herb, gamboges, potentilla discolor, rhubarb and liquoric root; soaking the thirty six traditional Chinese medicines into water, and decocting by mild fire, wherein the decocted soup is the traditional Chinese medicine for treating the constipation-predominant reflux esophagitis. The preparation method of the traditional Chinese medicine for treating the constipation-predominant reflux esophagitis has the advantages that the prepared traditional Chinese medicine liquid is small in side effect, short in course of treatment and high in cure rate.

The invention discloses a pharmaceutical composition containing sodium vitamin C and a preparation method thereof. The pharmaceutical composition contains the following components in parts by weight: 75-95 parts of sodium vitamin C, 5-10 parts of potassium chloride, pharmaceutically acceptable 0‑10 parts of accessories. The present invention overcomes the disadvantages of existing vitamin C such as high acidity and easy oxidation, and solves the clinical problem that potassium chloride produced by the combination of vitamin C and potassium chloride accelerates the oxidation of vitamin C, etc., so that the product has better stability and more definite curative effect It is suitable for patients who lack vitamin C and potassium in clinic. It can be used to treat scurvy, infectious diseases, purpura and other diseases with muscle weakness, paralysis, arrhythmia or renal dysfunction. It can also be used for malignant tumors, heart and brain. Prevention and adjuvant treatment of vascular diseases, infectious diseases, autoimmune diseases and other major difficult diseases.

The invention relates to a pure traditional Chinese medicine preparation for treating glomerular diseases. The pure traditional Chinese medicine preparation is prepared from the following raw materials in parts by weight: 30 parts of membranous milkvetch root, 12 parts of amur corktree bark, 15 parts of rhubarb, 40 parts of glabrous greenbrier rhizome, 20 parts of radix salviae miltiorrhizae, 15 parts of oriental waterplantain rhizome, 20 parts of epimedium herb, 15 parts of lalang grass rhizome and 30 parts of motherwort herb, and prepared by decoction, filtration, concentration of filtrate and drying. The pure traditional Chinese medicine preparation has significant efficacy for kidney diseases comprising acute and chronic glomerulonephritis, nephrotic syndrome, hypertensive nephropathy, diabetic nephropathy and early renal insufficiency caused by various reasons; furthermore, the raw materials are easily available, the production process is simple, the toxicity and side effects are small, and the administration is convenient, thereby providing the effective pure traditional Chinese medicine preparation for treating the kidney diseases.

Methods and compositions are provided for diagnosing of autosomal-dominant polycystic kidney disease (ADPKD), chronic kidney diseases, kidney dysfunction, and preeclampsia in a subject, preferably in a urine sample of a human subject. The methods and compositions enable the detection or measurement in the sample or from a protein profile generated from the sample, of RhoB protein or peptide fragments thereof. Comparing the protein level(s) of the RhoB protein or peptide fragments thereof in the subject's sample with the level of the same protein or peptide(s) in a reference standard, permits the determination of a diagnosis of ADPKD and other said diseases, or the identification of a risk of developing ADPKD and other said diseases, or enables the monitoring of the status of progression or remission of ADPKD and other said diseases in the subject.

The invention discloses composite Shenque moxibustion. The composite Shenque moxibustion is characterized by comprising a medical hot-melt pressure-sensitive adhesive located at the bottom, air permeable infiltration pores are distributed in the medical hot-melt pressure-sensitive adhesive, moxa floss composite medicine sticks to the middle of the medical hot-melt pressure-sensitive adhesive, and the outer layer of the moxa floss composite medicine is coated with tourmaline materials; the moxa floss composite medicine is prepared from, by weight, 80-95 parts of moxa floss, 3-5 parts of dried ginger, 1-5 parts of prepared common monkshood daughter roots, 0.5-1 part of halite and 2-5 parts of peach seeds, and the dried ginger, the prepared common monkshood daughter roots, the halite and the peach seeds which are in a powder form are mixed with the moxa floss. According to the composite Shenque moxibustion, positive stimulation to human bodies is achieved, the physique is strengthened greatly, the composite Shenque moxibustion can be used for sick bodies and healthy bodies, the function of promoting development of weak children is specially achieved, a good abdominal Qi transformation function is achieved, and the good curative effects on frequent micturition and urine waiting which are caused by senile prostatitis, hyperplasia and kidney dysfunction in Qi holding are achieved.

Methods are provided for treatment or prophylaxis of liver or kidney dysfunction in individuals experiencing one or more of intestinal failure, short bowel syndrome or parenteral nutrition by the administration of GLP-2 or GLP-2 analogs.

The purpose of the present invention is to provide a drug which is administered to patients suffering from chronic kidney disease that involves rapid progression of kidney dysfunction, in order to improve, or prevent the progression of, the disease state. The present invention relates to an agent for improving or preventing the progression of chronic kidney disease, the agent containing as the active ingredient 5-hydroxy-1-methyl hydantoin. This drug has exhibited a remarkable effect in patients suffering from chronic kidney disease that involves rapid progression of kidney dysfunction. This drug is extremely useful as a highly safe drug for improving, or preventing progression of, kidney dysfunction in patients suffering from rapidly progressing chronic kidney disease for which there have thus far been no effective therapeutic drugs that could be easily taken.

The present invention relates to methods and compositions for the treatment, management, or prevention of multiple myeloma and / or renal dysfunction in mammals. The methods of the invention comprise the administration of an effective amount of one or more pituitary adenylate cyclase activating polypeptide (“PACAP”) compounds, which includes PACAP, vasoactive intestinal peptide (“VIP”), their agonists, analogs, fragments, or derivatives, having one or more PACAP activities. The invention also provides pharmaceutical compositions comprising one or more PACAP compounds of the invention either alone or in combination with one or more other prophylactic / therapeutic agents useful in therapy for the treatment, management, or prevention of multiple myeloma and / or renal dysfunction.

The invention relates to a liver-benefiting kidney-tonifying stomach-invigorating tea and a preparation method thereof. The raw materials include herba dendrobii, dianthus chinensis, tartary buckwheat and wild roxburgh rose. The preparation method comprises the following steps: (1) drying and grinding herba dendrobii; (2) drying and grinding dianthus chinensis; (3) stir-frying and grinding tartary buckwheat; (4) drying and grinding wild roxburgh rose; (5) uniformly mixing in proportion to obtain dry tea; and (6) further grinding and preparing teabags. The liver-benefiting kidney-tonifying stomach-invigorating tea prepared by the method provided by the invention has the functions of clearing liver, improving vision, tonifying kidneys, strengthening essence, tonifying qi, moistening lung, prolonging life, resisting aging and fatigue and reducing blood glucose, blood lipid and blood pressure, and realizes a good healthcare effect, good mouthfeel and high nutritional value. The liver-benefiting kidney-tonifying stomach-invigorating tea provided by the invention is acceptable to the general population and particularly suitable for the people with hyperglycemia, hyperlipidemia, hypertension and liver-kidney dysfunction.

The present invention discloses one kind of nephropathy treating medicine composition and its preparation process. The Chinese medicine composition is prepared with Nippon yam rhizome, bupleurum root, angelica, astragalus root and leech. It is used in treating mesenchymal disease of glomerulum and renaltubule, chronic glomerulonephritis, renal disease, nephritic syndrome, etc. It has determined curative effect.

The application discloses LTBP2 as a new biomarker for renal dysfunction; methods for predicting, diagnosing, prognosticating and / or monitoring said dysfunction based on measuring said biomarker; and kits and devices for measuring said biomarker and / or performing said methods. LTBP2 is also involved in glomerular filtration rate, dyspnea, acute heart failure, left ventricular hypertrophy, cardiac fibrosis, preeclampsia, pregnancy- associated proteinuria.

The invention provides a formula for non-drug conditioning of obesity with hyperglycemia, hypertension, hyperlipemia and hyperuricemia. The formula comprises the following components: soybean proteinisolate, konjac powder, phosphatide, black soybean powder, red bean powder, oat powder, xylooligosaccharide, nutrient yeast, rhizoma dioscoreae powder, blueberry powder, an edible fungi solid concentrate and mixed nutrient powder. The particular formula is powder prepared by the following components in parts by weight: 20-30 parts of the soybean protein isolate, 5-10 parts of the konjac powder, 0.5-2 parts of the phosphatide, 0.01-0.1 part of the black soybean powder, 0.01-0.1 part of the red bean powder, 0.5-2 parts of the oat powder, 1-3 parts of the xylooligosaccharide, 0.1-1 parts of the nutrient yeast, 0.01-0.1 part of the rhizoma dioscoreae powder, 0.1-1 part of the blueberry powder, 0.1-1 part of the edible fungi solid concentrate and 1-2 parts of the mixed nutrient powder. The components in the formula can be applicable to middle aged and old people with hyperglycemia, hypertension, hyperlipemia and hyperuricemia after reasonable proportioning and can also be edible for other healthy and sub-health groups; and the components can also be applicable to people with cardio-cerebrovascular diseases (hypertension, hyperlipemia, arteriosclerosis and a coronary heart disease), diabetes (hyperglycemia), hyperuricemia, hepatic and renal dysfunction, a fatty liver disease and obesity.

The invention relates to a traditional Chinese medicinal composition for curing chronic renal insufficiency. The traditional Chinese medicinal composition comprises the following traditional Chinese medicinal raw materials, by weight, 10-40 parts of Radix Astragali, 10-30 parts of cistanche, 5-20 parts of tree peony bark, 5-25 parts of rhizoma alismatis, 10-40 parts of Gorgon fruit, 5-20 parts of cyathula root, 5-25 parts of morinda officinalis, 10-40 parts of Curculigo orchioides, 10-30 parts of Plantain seed, 10-40 parts of raw rehmannia root, 5-20 parts of radix paeoniae rubrathe, 10-30 parts of fleece-flower root, 10-40 parts of Chinese yam, 10-30 parts of Indian bread, 10-30 parts of white hyacinth bean, 10-40 parts of lotus seed, 5-20 parts of sophora bud, 5-25 parts of rhizoma Gastrodiae, 10-30 parts of serissa serissoide, 5-25 parts of semen persicae, 5-20 parts of semen astragali complanati, 10-30 parts of motherwort and 5-15 parts of licorice. The traditional Chinese medicinal composition has effects of nourishing liver, invigorating spleen, reinforcing kidney to strengthen yang, tonifying the kidney to control nocturnal emission with astringent drugs, invigorate blood circulation and nourishing blood, detoxifying and eliminating dampness, and has a remarkable curative effect of curing chronic renal insufficiency. The effects of the traditional Chinese medicinal composition are reliable.

The invention provides cordyceps mycelium tablets and a preparation method thereof. The cordyceps mycelium tablets comprise gymnadenia conopsea, fermented cordyceps mycelium powder, mulberry fruits and astragalus membranaceus, and have the effects of tonifying lung and kidney, secreting essence and tonifying qi. The cordyceps mycelium tablets are used for treating lung-kidney deficiency, essence and qi deficiency, chronic cough, asthenia asthma, fatigue, insomnia, amnesia, soreness and weakness of waist and knees, irregular menstruation, impotence, premature ejaculation and the like, as well as chronic bronchitis, chronic renal insufficiency, hyperlipidaemia, liver cirrhosis, tumors and other syndromes. Clinical research results of the gymnadenia conopsea cordyceps tablets show that the gymnadenia conopsea cordyceps tablets have remarkable effects of treating various chronic diseases and tumors of the nephrology department, the respiratory system and the endocrine system, bidirectionally adjusting immunity and the like.

The invention provides a composition for improving kidney dysfunction and belongs to the technical field of ginseng deep-processing. The composition comprises, by weight, 2-6 parts of ginsenoside Rg2,1-5 parts of ginsenoside Rg5 and 1-3 parts of ginsenoside Rk1. The composition participates in slowing down the progress of chronic kidney interstitial fibrosis by inhibiting HK-2 phenotypic differentiation so as to improve chronic kidney dysfunction. It is verified that the composition can remarkably improve kidney functions of patients at 2-3 stages of chronic kidney dysfunction CKD.

It is intended to provide a highly safe, orally administrable preventive and / or therapeutic agent for thrombosis and / or embolism that can be applied to a thrombosis and / or embolism patient with severe renal impairment. The present inventors have found that even for a thrombosis and / or embolism patient with severe renal impairment, use of edoxaban at a dose of 15 mg once a day can effectively prevent thrombosis and / or embolism while avoiding the risk of bleeding. The present inventors have also found that even for a thrombosis and / or embolism patient with severe renal impairment, edoxaban at a dose of 15 mg once a day can effectively prevent thrombosis and / or embolism with safety over a long period.

The invention discloses a traditional Chinese medicine composition for prevention and external treatment of diabetes and a use method. The traditional Chinese medicine composition for prevention and external treatment of the diabetes and the use method are characterized in that the traditional Chinese medicine composition is prepared from milkvetch roots, radix salviae miltiorrhizae, corn stigmas, cortex lycii, barbary wolfberry fruit, spica prunellae, folium mori, fructus corni, herba lycopodii, radix achyranthis bidentatae, rhizoma chuanxiong, rhizoma atractylodis, common yam rhizome, kudzuvine roots, fructus arctii and ramulus cinnamomi; the use method comprises the steps that 40-50 g / ml of medicine bag of Chinese herbal medicine powder or decoction is put into a foot bath, brewed with boiled water and stirred to be uniform, fumigation is conducted with traditional Chinese medicine steam for 10 min or above, and when the water is cooled to be at 40 DEG C to 42 DEG C, foot soaking is conducted for 30 min to 40 min; two feet are soaked once before sleeping each day, and a treatment course of foot soaking takes 20 days; by soaking the feet with the traditional Chinese medicine, blood glucose can be effectively reduced, polyuria,polydipsia and polyphagia of patients disappear, the body immunity can be improved, the immunity of the patients can be activated, and the self-healing ability of diseases is improved; uremia and the like caused by diabetic peripheral neuropathy, diabetic feet, diabetic nephropathy and renal insufficiency caused by the diabetes can be prevented.